Femasys FEMY
Femasys Q2 FY26: revenue $332K, down 19%; diluted EPS −$1.33
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001140361-26-033157
Key figures from this report
These are the numbers Femasys reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$332K−19% from $409K in Q2 FY2510-Q income statement, on EDGAR
- Net income−$4.5MAgainst −$4.6M in Q2 FY2510-Q income statement, on EDGAR
- Diluted EPS−$1.33Against −$3.20 in Q2 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$1.4M−55% from $3.2M in Q2 FY2510-Q balance sheet, on EDGAR
- Cash from operations−$3.9MAgainst −$4.4M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.
- DarioHealth DRIO public float $28M, Jun 30, 2025
- Cerenome CNSY public float $32M, Jun 30, 2025
- electroCore ECOR public float $28M, Jun 30, 2025
- QT Imaging Holdings QTI public float $33M, Jun 30, 2025
- Nephros NEPH public float $27M, Jun 30, 2025